Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fabagal in Fabry Disease
NCT06081062Phase 3Recruiting
- Sponsor
- ISU Abxis Co., Ltd.
- Start
- Apr 2023
- Primary completion
- Jun 2025
- Modality
- Replacement Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of agalsidase beta in Fabry disease (FD) (2 arms), sponsored by ISU Abxis Co., Ltd. Primary endpoint: Proportion of subjects achieving a GL-3 score of 0 in renal capillary endothelium histology at Day 336. Started Apr 2023; status: recruiting.
02
Drugs
agalsidase beta
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT06081062.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081062.